Latest News

  • Novel DNA Methylation Markers, Biosensor Aim for Early Detection of Cervical Cancer

    Diagnostics World |An international research consortium led by scientists from LMU University Hospital Munich has tested a new simple, rapid tuberculosis test that uses a blood sample from the fingertip. The candidate test, called the Cepheid Mycobacterium tuberculosis Host Response prototype cartridge (MTB-HR), works by measuring a three-gene transcriptomic signature.

    Dec 14, 2023
  • Living Biobank Of Brain Metastasis Samples Enabling ‘Personalized Medicine 2.0’

    Diagnostics World |Researchers at the CNIO (Spanish National Cancer Research Centre) are forwarding the idea that metastasis, rather than the primary tumor, should be the focus of cancer treatment, which would both further the cause of personalized medicine and generate biomarkers of sensitivity or resistance to specific drugs.

    Dec 13, 2023
  • Finger Prick Test Aims to Simplify Childhood Tuberculosis Diagnosis

    Diagnostics World |An international research consortium led by scientists from LMU University Hospital Munich has tested a new simple, rapid tuberculosis test that uses a blood sample from the fingertip. The candidate test, called the Cepheid Mycobacterium tuberculosis Host Response prototype cartridge (MTB-HR), works by measuring a three-gene transcriptomic signature.

    Dec 12, 2023
  • Prognostic Biomarker Scores Big For High-Risk Breast Cancer Cases

    Diagnostics World | Cytovale will bring its rapid sepsis diagnosis test to more hospital emergency departments (ED) and health systems in the United States; Elucid intends to expand its commercialization efforts to provide physicians and patients with critical information to combat heart disease; Flashpoint Therapeutics to advance its programs on Oncology, Peptide Therapeutics, and CRISPR; more.

    Dec 7, 2023
  • Researchers In Japan Identify High-Potential Biomarker Of Gastric Cancer

    Diagnostics World | Cytovale will bring its rapid sepsis diagnosis test to more hospital emergency departments (ED) and health systems in the United States; Elucid intends to expand its commercialization efforts to provide physicians and patients with critical information to combat heart disease; Flashpoint Therapeutics to advance its programs on Oncology, Peptide Therapeutics, and CRISPR; more.

    Dec 5, 2023